{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:11:20Z","timestamp":1787065880061,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.11.035","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T12:46:16Z","timestamp":1637325976000},"page":"7541-7544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine \u2013 United States, 2014\u20132018"],"prefix":"10.1016","volume":"39","author":[{"given":"Amy E.","family":"Blain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henju","family":"Marjuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Topaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mbaeyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.11.035_b0005","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease Surveillance Data Tables. https:\/\/www.cdc.gov\/meningococcal\/surveillance\/surveillance-data.html#figure01"},{"key":"10.1016\/j.vaccine.2021.11.035_b0010","unstructured":"Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2018. 2018"},{"key":"10.1016\/j.vaccine.2021.11.035_b0015","doi-asserted-by":"crossref","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR-9):1\u201341. DOI: 10.15585\/mmwr.rr6909a1","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"10.1016\/j.vaccine.2021.11.035_b0020","unstructured":"Clinical Update: Menomune (meningococcal polysaccharide vaccine) discontinuation. [cited 2021 Jan 4]. Available from: https:\/\/wwwnc.cdc.gov\/travel\/news-announcements\/menomune-discontinuation"},{"issue":"33","key":"10.1016\/j.vaccine.2021.11.035_b0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2014 United States, 2018","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2021.11.035_b0030","doi-asserted-by":"crossref","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","article-title":"Active bacterial core surveillance (ABCs) team and meningnet surveillance partners. effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2021.11.035_b0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Active bacterial core surveillance (ABCs) team and meningnet surveillance partners. early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine","volume":"30","author":"Macneil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.11.035_b0040","unstructured":"CDC. Meningococcal Disease (Neisseria meningitidis) 2015 Case Definition. [cited 2021 Jan 4]. Available from: https:\/\/wwwn.cdc.gov\/nndss\/conditions\/meningococcal-disease\/case-definition\/2015\/"},{"key":"10.1016\/j.vaccine.2021.11.035_b0045","unstructured":"WHO. 2011. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. WHO manual, 2nd ed. http:\/\/www.cdc.gov\/meningitis\/lab-manual\/full-manual.pdf."},{"issue":"5","key":"10.1016\/j.vaccine.2021.11.035_b0050","doi-asserted-by":"crossref","first-page":"e19361","DOI":"10.1371\/journal.pone.0019361","article-title":"sodC-based real-time PCR for detection of Neisseria meningitidis","volume":"6","author":"Dolan Thomas","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.035_b0055","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/JCM.06087-11","article-title":"Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens","volume":"50","author":"Wang","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2021.11.035_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.601870","article-title":"Web-based genome analysis of bacterial meningitis pathogens for public health applications using the bacterial meningitis genomic analysis platform (BMGAP)","volume":"11","author":"Buono","year":"2020","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.035_b0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.11.035_b0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"IMPAACT P1065 protocol team. phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.035_b0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","article-title":"International maternal pediatric adolescent AIDS clinical trials group P1065 protocol team. immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus","volume":"161","author":"Lujan-Zilbermann","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.11.035_b0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"IMPAACT P1065 protocol team. safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children","volume":"31","author":"Siberry","year":"2012","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:12Z","timestamp":1759403172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21014808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21014808"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine \u2013 United States, 2014\u20132018","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}